In March 2025, the company announced new plans for a immediate-to-customer offering of its Wegovy weight loss drug. The company recognized a whole new pharmacy, referred to as NovoCare, which would cost buyers $499 per month for entry to the drug, a lot less than 50 percent the expense of the drug via other pharmaceutical distribution networks.[53]